Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0680 + durvalumab versus nivolumab in advanced clear-cell renal cell carcinoma
NL-OMON47649Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) and kidney cancer comparing MEDI0680 + durvalumab, nivolumab monotherapy and MEDI0680 monotherapy (3 arms). Primary endpoint: Objective response. Started Mar 2018; status: active, not recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)kidney cancer
Beyond the preview
Go deeper on NL-OMON47649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47649.